ClinicalTrials.gg
Sign In
RecruitingNCT07885189TuCAN-MediaUpdated Oct 21, 2026

Long-Term Cognitive Recovery After Arteria Cerebri Media Ischemia: A Digital Assessment Using the TuCAN-App

An observational study in Cognitive Recovery After Stroke and Cognitive Outcome After Stroke, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University Hospital Tuebingen · Observational

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 21, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

TuCAN-Media is a longitudinal study investigating cognitive recovery after stroke in severely affected patients (modified Rankin Scale [mRS] score ≥ 3) with large vessel occlusion of the arteria cerebri media/middle cerebral artery (MCA). Cognitive functioning and recovery will be assessed in a comprehensive multi-domain digital-based cognitive testing using the TuCAN-App to facilitate a standardized and rapid testing during the acute phase of a stroke (V2), as well as at 3month(V3)- and 6-month (V4) follow-ups.

02

Conditions studied

  • Cognitive Recovery After Stroke
  • Cognitive Outcome After Stroke

Keywords

  • cognitive outcome after stroke
  • cognitive recovery after stroke
  • cognitive assessment in stroke patients
  • digital-based cognitive assessment
03

In context

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 490 studies on the registry; 108 are open to participants now.

Browse University Hospital Tuebingen studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

primary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age
  • Right- or left-hemispheric MCA occlusion (MCA segments M1-M3 or corresponding perfusion deficit)
  • modified Rankin Scale (mRS) score ≥ 3 at the time of the index event
  • Informed consent from the patient or their legal representative

Exclusion criteria

Exclusion Criteria:

  • ≤ 18 years of age
  • Pregnancy
  • Pre-existing severe dementia
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Rec+

    after successfull recanalization (thrombectomy)

  • Rec-

    after unsucessfull recanalization (thrombectomy)

06

What researchers measure

Primary outcomes

  1. Group comparision (Rec+ vs. Rec-) of cognitive function between acute stroke and at 3 month follow-up

    Group comparison of cognitive function between visit 2 (V2) and visit 3 (V3) in patients with and without successful recanalization as assessed by the St. Louis University Mental Status (SLUMS) examination total score

    Time frame: 3 months

Secondary outcomes

  1. Group comparision (Rec+ vs. Rec-) of cognitive function between 3 months and 6 months follow-up

    Group comparison of cognitive function between 3 months and 6 months follow up in patients with successful versus unsuccessful recanalization as assessed by the St. Louis University Mental Status (SLUMS) examination total score

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Oct 21, 2026
StartActual
Jul 1, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07885189
Lead sponsor
University Hospital Tuebingen
Collaborators
Sigrid Oergel Foundation
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Jul 1, 2025
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University Hospital Tuebingen →

Start the discussion